Verastem (VSTM) CFO Daniel Calkins Sells $17K of Stock

On June 22, 2026, Verastem, Inc.'s Chief Financial Officer, Daniel Calkins, sold 4,089 shares of the company in a planned transaction. The shares were sold at an average price of $4.18, bringing the total value of the transaction to about $17,089. As of Thursday, Verastem shares were trading at approximately $4.21.

Insider Buying and Selling at Verastem, Inc.

Daniel Calkins, the CFO of Verastem, executed a planned sale of 4,089 shares on June 22, 2026, at an average price of $4.18. This transaction was part of a Rule 10b5-1 trading plan, which allows company insiders to sell a predetermined number of shares at a set time. On the same day, President and CEO Dan Paterson also sold 20,871 shares under a similar plan.

Other Institutional Activity in Verastem, Inc.

Several institutional investors have been active in Verastem. BlackRock, Inc. increased its holdings by 1,442,083 shares, reaching a total of 6,194,925 shares valued at about $32.8 million, a 30.3% increase. Armistice Capital, LLC added 1,056,000 shares, resulting in 4,592,000 shares worth approximately $24.3 million, marking a 29.9% increase. Nantahala Capital Management, LLC significantly boosted its position by 3,122,680 shares to 3,584,820 shares, a 675.7% rise, with a value of $19.0 million.

Verastem, Inc. Stock Down 43.4%

Shares of NasdaqCM:VSTM traded near $4.21 on Thursday. Verastem, Inc. has a market capitalization of $373.5 million and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock has a 52-week low of $3.55 and a high of $11.25, with a 50-day moving average of $4.90 and a 200-day moving average of $7.04. The company's current ratio stands at 3.035, and its debt-to-equity ratio is 104.52.

Analysts Set New Price Targets

On June 24, 2026, BTIG reiterated its buy rating on Verastem, setting a price target of $18. Jefferies maintained its buy rating with a target of $8 on June 23, 2026. The overall consensus from analysts is a strong buy, with a mean target price of $16, based on eight analyst opinions.

About Verastem, Inc.

Verastem, Inc., headquartered in Needham, Massachusetts, is a biotechnology company focused on developing cancer treatments. The company is actively working on drugs like Avutometinib and Defactinib for various cancers. Led by CEO Daniel W. Paterson, Verastem engages in multiple clinical trials and has partnerships with major pharmaceutical firms like Pfizer and Amgen. The company employs 102 people.

Bottom Line

Insider transactions like the recent sale by Verastem's CFO are closely monitored by investors for potential insights into company performance. While such sales are often pre-planned, they can still influence market perceptions. Verastem remains a company of interest due to its active development pipeline and strategic partnerships. As always, remember that 13F filings and insider transactions are backward-looking and may not reflect the current state of holdings.